Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura, Nobutaka Nakamura, Takahiro Yamada, Sachiko Yanagida, Asami Kitaoka, Kiyotaka Kojima, Hiroyasu Sugano, Seigo Kinuya, Tomio Inoue, Jun Hatazawa, Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura, Nobutaka Nakamura, Takahiro Yamada, Sachiko Yanagida, Asami Kitaoka, Kiyotaka Kojima, Hiroyasu Sugano, Seigo Kinuya, Tomio Inoue, Jun Hatazawa

Abstract

Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.

Keywords: Lu-177-DOTA-TATE; Neuroendocrine tumor; Radionuclide therapy.

References

    1. Release of Patients who have been Administered a Radiopharmaceutical (Notice No. 1108–2 from the Division for Guidance on Medical Care, Health Policy Bureau dated November 8, 2010, Notice from the Head of the Division for Guidance on Medical Care, Health Policy Bureau, Ministry of Health, Labor, and Welfare).
    1. Release of Patients who have been Administered a Radiopharmaceutical (Notice No. 70 from the Safety Division, Pharmaceutical and Medical Safety Bureau dated June 30, 1998, Notice from the Head of the Safety Division, Pharmaceutical and Medical Safety Bureau.
    1. Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney. World J Surg. 2010;34(6):1368–1372. doi: 10.1007/s00268-009-0387-6.
    1. Kwekkeboom D, de Herder W, Kam B, van Eijck C, van Essen M, Kooij P, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130. doi: 10.1200/JCO.2007.15.2553.
    1. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–2135. doi: 10.1007/s00259-011-1902-1.
    1. . A study comparing treatment with 177Lu-DOTA0-Tyr3-octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1). .
    1. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP. 1988;18(1–4).
    1. ICRP Publication 60. Recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21(1–3).
    1. ICRP Publication 73. Radiological protection and safety in medicine. Ann ICRP. 1996;26(2).
    1. ICRP Publication 94. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34(2).
    1. International basic safety standards for protection against ionizing radiation and for the safety of radiation sources, IAEA safety series, no. 115, 1996.
    1. Handbook of chemistry: pure chemistry. 5th ed. Chemical Society of Japan; 2004.
    1. ICRP Publication 30 (Part 3). Limits for intakes of radionuclides by workers. Ann ICRP. 1981;6(2–3).
    1. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406–416. doi: 10.1089/cbr.2006.325.
    1. Sandström M, Garske-Román U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41. doi: 10.2967/jnumed.112.107524.
    1. Enforcement of a Ministerial Ordinance partially amending the Ordinance for Enforcement of the Medical Services Act (Notice No. 188 of the Pharmaceutical and Food Safety Bureau dated March 12, 2001, Notice from the Director General of the Pharmaceutical and Food Safety Bureau, Ministry of Health, Labor, and Welfare).
    1. ICRP Publication 103. The 2007 recommendations of the international commission on radiological protection. Ann ICRP. 2007;37(2–4).
    1. Release of Patients who have been Administered a Radiopharmaceutical (Office Memorandum dated June 30, 1998, Safety Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare). .
    1. Koshida K, Koga S, et al. Criteria for discharge of patients undergoing 131I treatment and criteria for release to regular patient rooms based on the dose of external exposure. Nucl Med. 1989;26:591–599.
    1. Archer J, Carroll M, Vinjamuri S. Clearance of 177Lu-DOTATATE from patients receiving peptide receptor radionuclide therapy. RAD Mag. 2013;39:45513–45515.
    1. 2014 Statistics on Japan, Statistics Bureau, Ministry of Internal Affairs and Communications. 2014.
    1. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50(1):58–64. doi: 10.1007/s00535-014-0934-2.
    1. Guidelines for drinking-water quality. Vol. I. Recommendations, WHO. 2008.
    1. Methods of measuring radiation doses radiology technologists and technicians are exposed to and methods of calculating the effective dose and equivalent dose (Notification No. 398 from the Ministry of Health and Welfare dated December 26, 2000).
    1. Handling the diapers of patients who have been administered a radiopharmaceutical (guidelines for medical personnel working in nuclear medicine) (March 2001, 1st ed., March 2004, 2nd ed.), Japanese Society of Nuclear Medicine, Japan Radiological Society, Japan Society of Radiological Technology, Japanese Society of Nuclear Medicine Technology, Japan Association on Radiological Protection in Medicine. .
    1. Law on the Prevention of Radiation Injuries Due to Radioisotopes (law no. 167 dated June 10, 1957).
    1. Medical Services Act (law no. 205 dated July 30, 1948).
    1. Ordinance for Enforcement of the Medical Services Act (Ministry of Health and Welfare Ordinance No. 50 dated November 5, 1948).
    1. Ordinance on Prevention of Ionizing Radiation Injuries (Ministry of Labor Ordinance No 41 dated September 30, 1972).
    1. Rule 10-5 of the National Personnel Authority (prevention of radiation injuries to personnel) (rule 10-5 of the National Personnel Authority dated September 25, 1963).
    1. Guidelines on the Management of Radioisotope Concentrations in Emissions and Effluent, Japan Radiological Society, Japan Society of Radiological Technology, Japanese Society of Nuclear Medicine, Japanese Society of Nuclear Medicine Technology, April 2001. .
    1. John J, Zaknun L, Bodei J, Mueller-Brand ME, Pavel RP, Baum D, Horsch, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–816. doi: 10.1007/s00259-012-2330-6.
    1. Manual on Management of Medical Radiation, Revised ed. Japan Radioisotope Association, 2004.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner